title: Low-molecular-weight hormonal factors that affect head formation in Hydra.
abstract: Support or inhibition of DAG-induced head formation: Hydra magnipapillata can be caused to form ectopic head structures by periodictreatmentwith PKC activators such as diacylglycerol (DAG). This ectopic head formation is supported by an extract from the ovine pineal gland that contains low-molecular-weight compounds. The frequency of ectopic head formation is also increased when DAG is paired with one of several lipophilic hormonal factors: (1) pinoline, a putative pineal hormone derived from tryptophan, (2) 12-S-HETE, a paracrine derivative of arachidonic acid, or (3) 1alpha, 25 dihydroxyvitamine D3, a hormonal factor also known as calcitriol. Dose-response curves were non-monotonic passing a maximum at low dosages. By contrast, DAG lost its capacity to induce ectopic head structures when it was paired with the provitamin D3, cholecalciferol. Patterning the head: one eicosanoid was found which influences patterning without being combined with DAG: 12-R-HETE caused growth-based elongation of the tentacles and an increase in the number of tentacles without affecting the longitudinal body pattern. Similar effects are brought about by substances that interfere with tyrosine phosphorylation, most potently bythe phosphotyrosine phosphatase inhibitor bisperoxo-(1,10-phenanthroline)-oxovanadate (V). The results speak for the existence of head-inducing hormonal factors, underline the significance of content protein kinases to pattern formation and point to a negative influence of the vitamin D3 content of the food on the capacity of the animals to develop head structures.
authors.affiliation: Zoological Institute, Physiology University, Heidelberg, Germany. W.MULLER@sirius.mgen.uni-heidelberg.de
authors.forename: W A
authors.initials: WA
authors.lastname: Müller
authors.forename: C
authors.initials: C
authors.lastname: Bartsch
authors.forename: H
authors.initials: H
authors.lastname: Bartsch
authors.forename: I
authors.initials: I
authors.lastname: Maidonis
authors.forename: E
authors.initials: E
authors.lastname: Bayer
mesh_terms: D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid / Q000494:pharmacology; D000818:Animals; D016227:Benzoquinones; D002117:Calcitriol / Q000494:pharmacology; D002243:Carbolines / Q000494:pharmacology; D002457:Cell Extracts / Q000494:pharmacology*; D002762:Cholecalciferol / Q000494:pharmacology; D004075:Diglycerides / Q000494:pharmacology; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006257:Head / Q000254:growth & development; D006728:Hormones / Q000737:chemistry / Q000494:pharmacology*; D006829:Hydra / Q000187:drug effects*; D047029:Lactams, Macrocyclic; D008970:Molecular Weight; D010870:Pineal Gland / Q000737:chemistry*; D011493:Protein Kinase C / Q000378:metabolism; D011809:Quinones / Q000494:pharmacology; D017828:Rifabutin / Q000031:analogs & derivatives; D014638:Vanadates / Q000494:pharmacology; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
chemical_list: D016227:Benzoquinones; D002243:Carbolines; D002457:Cell Extracts; D004075:Diglycerides; D004791:Enzyme Inhibitors; D006728:Hormones; D047029:Lactams, Macrocyclic; D011809:Quinones; C044295:1,2-dioctanoylglycerol; D002762:Cholecalciferol; D017828:Rifabutin; C002272:6-methoxytryptoline; D014638:Vanadates; D019377:12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; C020754:herbimycin; D019061:src-Family Kinases; D011493:Protein Kinase C; D002117:Calcitriol